Knight Therapeutics Secures Colombian Approval for TAVALISSE in Chronic ITP Treatment
Event summary
- Knight Therapeutics received regulatory approval from Colombia's INVIMA for TAVALISSE (fostamatinib) to treat chronic immune thrombocytopenia (ITP) in adults.
- The approval follows a 2022 agreement with Rigel Pharmaceuticals for exclusive Latin American commercialization rights.
- Knight has submitted TAVALISSE for approval in Brazil, Mexico, Argentina, and Paraguay, with launches planned in Mexico (May 2026) and Brazil (Q4 2026).
- Colombia launch is expected in the first half of 2027.
The big picture
Knight's approval in Colombia strengthens its position in the Latin American pharmaceutical market, particularly in specialty therapies for rare blood disorders. The company's strategy of securing exclusive rights to innovative treatments aligns with broader industry trends of regional market expansion through targeted regulatory and commercialization efforts. Success in these markets could position Knight as a key player in Latin America's growing demand for advanced therapeutic options.
What we're watching
- Regulatory Momentum
- The pace at which Knight secures approvals in other Latin American markets will determine its commercialization timeline.
- Market Penetration
- Whether Knight can effectively compete with existing ITP treatments in Colombia and other approved markets.
- Execution Risk
- How Knight manages the operational challenges of launching TAVALISSE across multiple Latin American countries simultaneously.
Related topics